For more than a century, the Somatic Mutation Theory (SMT) of cancer—first articulated by German cytologist Theodor Boveri in 1914—has defined our framework for understanding cancer. The premise was deceptively simple: genetic mutations accumulate in cells, disrupting growth controls and transforming them into malignant clones. The elegance of the theory, bolstered by the advent of sequencing technologies and the Human Genome Project, promised that once we could map and drug these mutations, cancer would be conquered.

Yet the reality has been sobering. Decades of research and billions of dollars later, precision oncology has delivered incremental progress, not sweeping cures. Even more disquieting, nuclear transfer experiments—in which the nucleus of a malignant cell is transplanted into the cytoplasm of a healthy cell—have failed to produce malignant offspring. The healthy cytoplasm, with its intact mitochondria and metabolic machinery, appears to reassert order over the damaged nucleus. If cancer were strictly a nuclear, genetic disease, these results should have yielded malignant progeny. They did not.

This disconnect has forced the field to broaden its lens. Even Siddhartha Mukherjee, Pulitzer Prize-winning author of The Emperor of All Maladies, The Gene, and The Song of the Cell, has subtly but notably shifted his emphasis over the years. While his early works highlight cancer as a genetic disease, his most recent writing underscores that genes operate within an ecological and metabolic context—that the cytoplasm, mitochondria, and the microenvironment cannot be ignored.

At the same time, public conversation has caught up with science. In Ravenous, journalist Sam Apple resurrected the controversial story of Otto Warburg, the brilliant German scientist who in the 1920s identified that cancer cells ferment glucose in the presence of oxygen—a phenomenon now known as the “Warburg effect.” Warburg’s work was dismissed for decades, overshadowed by the glamour of genetics and clouded by his problematic political affiliations. Apple’s book reintroduced Warburg to a modern audience, positioning his ideas not as relics but as precursors to today’s cutting-edge research in cancer metabolism.

That research is being turbocharged by modern tools Warburg never had. Seahorse analyzers, which can track real-time mitochondrial respiration and glycolytic flux, have become staples of oncology labs. Metabolomics, the large-scale profiling of metabolites within cells and fluids, is revealing the precise nutrient dependencies of tumors and the microenvironmental signatures that distinguish aggressive from indolent disease. Together, these tools confirm that metabolism is not simply a byproduct of cancer—it is a driver, and increasingly, a target.

The Rise of Metabolic Oncology

This renewed interest has crystallized into a field often referred to as metabolic oncology—an integrative, systems-based approach that recognizes cancer as, at its root, a disease of deranged metabolism. Genes matter, but they matter within context. Mutations may be passengers rather than drivers, or their impact may be dictated by whether mitochondria are healthy, whether oxygenation is adequate, and whether nutrient and redox balances are maintained.

The mitochondrial metabolic theory of cancer, advanced most prominently by Dr. Thomas N. Seyfried, provides a comprehensive explanation: damaged mitochondria impair oxidative phosphorylation, forcing cells to rely on substrate-level phosphorylation (fermentation of glucose and glutamine). This shift alters redox signaling, destabilizes the genome, and creates a feedback loop of metabolic chaos. Seyfried’s work has expanded Warburg’s insight into a full-fledged therapeutic framework.

One of Seyfried’s key contributions is the concept of press–pulse therapy. Here, the tumor is continuously “pressed” by restricting its fermentable fuels (via ketogenic nutrition, glycemic control, or caloric restriction), while being intermittently “pulsed” with additional stressors—hyperbaric oxygen, heat, oxidative therapies, or carefully selected drugs—that exploit the tumor’s inflexibility. This contrasts starkly with the maximum tolerated dose (MTD) paradigm of conventional oncology, which indiscriminately blasts both tumor and host, often leaving patients debilitated.

Building on this foundation, Drs. Angela Poff and Dominic D’Agostino at the University of South Florida demonstrated in elegant preclinical models that combining a ketogenic diet with hyperbaric oxygen therapy significantly slowed metastatic cancer growth and improved survival in mice compared to either strategy alone. Their work illustrated a core tenet of metabolic oncology: when therapies are layered thoughtfully, the whole is greater than the sum of its parts.

Across the Atlantic, Dr. Isabella Cooper has championed the importance of hyperinsulinemia and the insulin/IGF axis as central drivers of cancer metabolism. By highlighting how modern diets fuel growth signaling, inflammation, and metabolic inflexibility, Cooper’s contributions have bridged metabolic theory with clinical metabolic markers—fasting insulin, HOMA-IR, and post-prandial dynamics—that can be measured and modified in real patients.

And in the clinic, pioneers like Dr. Ahmed Elsakka have translated theory into practice. Elsakka’s 2018 case report of a 38-year-old glioblastoma patient integrated ketogenic therapy, preoperative fasting, and hyperbaric oxygen alongside standard of care, yielding a favorable outcome and offering a real-world model for safe integration of metabolic strategies into oncology.

I have also been privileged to add my own voice to this movement through The Metabolic Approach to Cancer, which I co-authored with Jess Higgins. Our book distilled the Terrain Ten framework—ten modifiable aspects of physiology and lifestyle that influence the cancer process, from glycemic control and epigenetics to circadian rhythm and the microbiome. This approach, rooted in the principle of Test, Assess, Address™, provides clinicians and patients with a roadmap for integrating metabolic and terrain-based strategies into oncology. It emphasizes not just treatment but wellness creation and cancer prevention, reframing oncology as more than a reaction to disease.

Why Metabolism Matters

To the practicing clinician, the implications of this shift are profound. If cancer is, in large part, a disease of metabolism, then we must learn to test, assess, and address metabolism as carefully as we do genetics. This means:

• Measuring glycemic control: fasting insulin, glucose/ketone indices, and continuous monitoring;
• Tracking mitochondrial function proxies: lactate/pyruvate ratios, organic acid testing;
• Assessing nutrient and redox status: vitamin D3, magnesium, selenium, CoQ10, tocopherols/tocotrienols;
• Evaluating circadian and autonomic health: heart rate variability, cortisol rhythms, sleep cycles;
• Identifying environmental stressors: toxins, chronic infections, hypoxia, and microbiome disruption.

This terrain-focused approach does not replace oncology. It refines it, providing new levers for intervention and new markers for monitoring. Therapies like ketogenic nutrition, fasting strategies, hyperbaric oxygen, hyperthermia, and mitochondrial support can be paired with surgery, chemotherapy, immunotherapy, and radiation—not in opposition, but in synergy.

Indeed, adaptive therapy models being developed at institutions like Moffitt Cancer Center—where treatment is titrated to suppress resistant clones rather than eradicate all cells at once—mirror the press–pulse philosophy of metabolic oncology. Both approaches share a guiding principle: apply pressure intelligently, respect biology’s feedback loops, and work with the system, not against it.

A Paradigm in Transition

Recent publications in the Nature family of journals have acknowledged this transition, noting that the somatic mutation theory is no longer sufficient as a unifying explanation of cancer, and that metabolic vulnerabilities offer more promising avenues for intervention. While no serious scientist denies that genes play a role, it is increasingly clear that they operate within a metabolic context. In other words, SMT is not dead, but it has been dethroned as the sole narrative.

As the science evolves, so must our care models. Patients deserve therapies that exploit tumor vulnerabilities while supporting systemic resilience. That is the promise of metabolic oncology: not to discard the advances of molecular oncology, but to embed them within the living, breathing metabolic terrain of the patient.

The Future: From Bench to Bedside

What excites me most is how this science is becoming measurable, actionable, and personalized:

• Seahorse analyzers allow us to quantify mitochondrial respiration in real time, testing whether therapies restore healthy oxidative phosphorylation.
• Metabolomics platforms profile hundreds of metabolites in a single assay, providing fingerprints of tumor fuel use and redox stress.
• Adaptive clinical models let us tailor interventions dynamically, ensuring the right “press” and the right “pulse” at the right time.

Together, these tools point toward a future where oncology is no longer a one-size-fits-all protocol, but a metabolic choreography, designed to restore balance in the patient while destabilizing the tumor.

An Invitation: Metabolic Health Day

This October, we will gather for the Metabolic Health Day Conference—a meeting dedicated to translating this science into clinical practice. We will explore how to measure metabolism, how to apply dietary and lifestyle interventions safely, how to combine oxygen, heat, and nutrient therapies with standard of care, and how to design personalized press–pulse protocols for real patients.

The field of metabolic oncology is no longer fringe. It is the frontier. And together, we have the opportunity to make cancer care more effective, more humane, and more hopeful.

EDITOR’s NOTE: This is an important conference that Townsend Letter will be attending. To join us, visit the MTIH Registration Page at this link. See you there! OCTOBER 10-11, 2025.

Endnotes

1. Boveri T. Concerning the Origin of Malignant Tumours. 1914.
2. McKinnell RG, Deggins BA, Labat DD. “Transplantation of nuclei from triploid frog tumors.” Cancer Research. 1969.
3. Mukherjee S. The Emperor of All Maladies. Scribner, 2010.
4. Mukherjee S. The Gene: An Intimate History. Scribner, 2016.
5. Mukherjee S. The Song of the Cell. Scribner, 2022.
6. Apple S. Ravenous: Otto Warburg, the Nazis, and the Search for the Cancer-Diet Connection. Liveright, 2021.
7. Warburg O. “On the origin of cancer cells.” Science. 1956;123(3191):309–314.
8. Seyfried TN. Cancer as a Metabolic Disease. Wiley, 2012.
9. Seyfried TN, Shelton LM. “Cancer as a metabolic disease.” Nutrition & Metabolism. 2010.
10. Seyfried TN, et al. “Press-pulse therapeutic strategy for the metabolic management of cancer.” Nutrition & Metabolism. 2017.
11. Poff AM, et al. “The ketogenic diet and hyperbaric oxygen therapy prolong survival in mice with systemic metastatic cancer.” PLOS ONE. 2013.
12. Cooper I. “Insulin and cancer metabolism: connecting the dots.” Lecture, 2019.
13. Elsakka AM, et al. “Managing glioblastoma multiforme with ketogenic metabolic therapy: a case report.” Frontiers in Nutrition. 2018.
14. Winters N, Kelley JH. The Metabolic Approach to Cancer: Integrating Deep Nutrition, the Ketogenic Diet, and Non-Toxic Bio-Individualized Therapies. Chelsea Green, 2017.
15. Gatenby RA, et al. “Adaptive therapy.” Cancer Research. 2009.
16. Springer Nature Editors. “Cancer Metabolism 2.0.” Springer Nature Cancer Portfolio. 2023.